Hydrocodone Bitartrate Patent Expiration
Hydrocodone Bitartrate was first introduced by Recro Gainesville Llc
Hydrocodone Bitartrate Patents
Given below is the list of patents protecting Hydrocodone Bitartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zohydro Er | US10092559 | Abuse resistant pharmaceutical compositions | Sep 12, 2034 | Recro Gainesville |
| Zohydro Er | US9132096 | Abuse resistant pharmaceutical compositions | Sep 12, 2034 | Recro Gainesville |
| Zohydro Er | US9452163 | Abuse resistant pharmaceutical compositions | Sep 12, 2034 | Recro Gainesville |
| Zohydro Er | US9486451 | Abuse resistant pharmaceutical compositions | Sep 12, 2034 | Recro Gainesville |
| Zohydro Er | US9713611 | Abuse resistant pharmaceutical compositions | Sep 12, 2034 | Recro Gainesville |
| Zohydro Er | US10028946 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Zohydro Er | US10322120 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Zohydro Er | US10456393 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Zohydro Er | US10722511 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Zohydro Er | US9265760 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Zohydro Er | US9326982 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Zohydro Er | US9333201 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Zohydro Er | US9339499 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Zohydro Er | US9421200 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Zohydro Er | US9433619 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Zohydro Er | US9610286 | Treating pain in patients with hepatic impairment | Jul 25, 2033 | Recro Gainesville |
| Hysingla Er | US8808740 | Encased tamper resistant controlled release dosage forms | Dec 21, 2031 | Purdue Pharma Lp |
| Hysingla Er | US9572779 | Encased tamper resistant controlled release dosage forms | Dec 21, 2031 | Purdue Pharma Lp |
| Hysingla Er | US9750703 | Encased tamper resistant controlled release dosage forms | Dec 21, 2031 | Purdue Pharma Lp |
| Hysingla Er | US9861584 | Tamper resistant controlled release dosage forms | Dec 21, 2031 | Purdue Pharma Lp |
| Hysingla Er | US9872837 | Tamper resistant controlled release dosage forms | Dec 21, 2031 | Purdue Pharma Lp |
| Vantrela Er | US8445018 | Abuse resistant drug formulation | Jul 31, 2029 | Teva Branded Pharm |
| Vantrela Er | US9216176 | Abuse resistant drug formulation | Sep 13, 2027 | Teva Branded Pharm |
| Vantrela Er | US9572803 | Abuse resistant drug formulation | Sep 13, 2027 | Teva Branded Pharm |
| Hysingla Er | US11304908 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US11304909 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9084816 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9095614 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9095615 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9486412 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9486413 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9492389 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9492390 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9492391 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9545380 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9763933 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9770416 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US9775809 | Tamper resistant dosage forms | Aug 24, 2027 | Purdue Pharma Lp |
| Hysingla Er | US11844865 | Abuse-proofed oral dosage form | Feb 13, 2025 | Purdue Pharma Lp |
| Hysingla Er | US10130591 | Abuse-proofed dosage form |
Nov 20, 2023
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US8309060 | Abuse-proofed dosage form |
Nov 20, 2023
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US10369109 | Abuse-proofed dosage form |
Jun 16, 2023
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9675610 | Abuse-proofed dosage form |
Jun 16, 2023
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US8529948 | Pharmaceutical formulation containing gelling agent |
Aug 06, 2022
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US6733783 | Controlled release hydrocodone formulations |
Oct 30, 2021
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US8361499 | Controlled release hydrocodone formulations |
Oct 30, 2021
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US8551520 | Controlled release hydrocodone |
Oct 30, 2021
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US8647667 | Controlled release hydrocodone formulations |
Oct 30, 2021
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9023401 | Controlled release hydrocodone formulations |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9056052 | Controlled release hydrocodone formulations |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9060940 | Controlled release hydrocodone |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9198863 | Controlled release hydrocodone formulations |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9205056 | Controlled release hydrocodone formulations |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9289391 | Controlled release hydrocodone formulations |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9517236 | Controlled release hydrocodone formulations |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9572804 | Controlled release hydrocodone formulations |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9669023 | Controlled release hydrocodone formulations |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9669024 | Controlled release hydrocodone formulations |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9675611 | Methods of providing analgesia |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Hysingla Er | US9682077 | Methods of providing analgesia |
Oct 30, 2020
(Expired) | Purdue Pharma Lp |
| Zohydro Er | US6228398 | Multiparticulate modified release composition |
Nov 01, 2019
(Expired) | Recro Gainesville |
| Zohydro Er | US6902742 | Multiparticulate modified release composition |
Nov 01, 2019
(Expired) | Recro Gainesville |
| Hysingla Er | US6488963 | Hot-melt extrudable pharmaceutical formulation |
Jun 24, 2017
(Expired) | Purdue Pharma Lp |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Hydrocodone Bitartrate's patents.
Latest Legal Activities on Hydrocodone Bitartrate's Patents
Given below is the list recent legal activities going on the following patents of Hydrocodone Bitartrate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed Critical | 01 Jul, 2024 | US9486451 |
| Maintenance Fee Reminder Mailed Critical | 20 May, 2024 | US9452163 |
| Maintenance Fee Reminder Mailed Critical | 29 Apr, 2024 | US9433619 |
| Maintenance Fee Reminder Mailed Critical | 15 Apr, 2024 | US9421200 |
| Maintenance Fee Reminder Mailed Critical | 18 Mar, 2024 | US10722511 |
| Expire Patent Critical | 29 Jan, 2024 | US9216176 |
| Expire Patent Critical | 04 Dec, 2023 | US10456393 |
| Maintenance Fee Reminder Mailed Critical | 14 Aug, 2023 | US9216176 |
| Expire Patent Critical | 24 Jul, 2023 | US10322120 |
| Maintenance Fee Reminder Mailed Critical | 19 Jun, 2023 | US10456393 |
Hydrocodone Bitartrate's Family Patents
Explore Our Curated Drug Screens
Hydrocodone Bitartrate Generic API Manufacturers
Several generic applications have been filed for Hydrocodone Bitartrate.
Given below is the list of companies who have filed for Hydrocodone Bitartrate generic, along with the locations of their manufacturing plants worldwide.
1. ALVOGEN
Alvogen Inc has filed for 10 different strengths of generic version for Hydrocodone Bitartrate. Given below are the details of the strengths of this generic introduced by Alvogen.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | tablet, extended release | Prescription | ORAL | AB | Mar 1, 2021 |
| 10MG
(reference standard) | capsule, extended release | Prescription | ORAL | N/A | Jan 21, 2020 |
| 15MG | capsule, extended release | Prescription | ORAL | N/A | Jan 21, 2020 |
| 30MG | tablet, extended release | Prescription | ORAL | AB | Mar 1, 2021 |
| 40MG | tablet, extended release | Prescription | ORAL | AB | Mar 1, 2021 |
| 50MG | capsule, extended release | Prescription | ORAL | N/A | Jan 21, 2020 |
| 60MG | tablet, extended release | Prescription | ORAL | AB | Mar 1, 2021 |
| 80MG | tablet, extended release | Prescription | ORAL | AB | Mar 1, 2021 |
| 100MG | tablet, extended release | Prescription | ORAL | AB | Mar 1, 2021 |
| 120MG | tablet, extended release | Prescription | ORAL | AB | Mar 1, 2021 |
Manufacturing Plant Locations New
Alvogen's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Alvogen as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||